Redx Pharma plc - New in vivo data on ROCK2
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN
("Redx" or "the Company")
New in vivo data suggests ROCK2 has broad potential in fibrosis
First-in-man studies, targeting NASH, planned for 2020
Redx reports new data from three independent preclinical animal models of lung, kidney and liver fibrosis, which show that the Company's lead ROCK2 compound, dosed therapeutically once fibrosis is initiated, was able to suppress collagen deposition and pathways associated with fibrosis, indicating that selective ROCK2 inhibition can have an impact on established fibrosis. The data from separate studies suggest that Redx's compound possesses a suitable pharmacokinetic profile for an orally bioavailable drug and has a low propensity to inhibit key drug metabolising Cytochrome P450 enzymes, making it less likely to interact with other drugs. The data from these studies will be presented later in 2019 at a scientific meeting.
Following final safety evaluations, the Company plans to nominate a drug candidate for the ROCK2 programme by mid 2019. If nominated for development, the novel selective ROCK2 inhibitor will be developed as an orally administered, first-in-class treatment for the non-alcoholic steatohepatitis (NASH) with first-in-man studies commencing in 2020. NASH is a progressive disease of the liver caused by a build-up of fatty deposits leading to inflammation, tissue damage, tissue remodelling and fibrosis, reducing the metabolic function of the liver. There are currently no approved treatments for NASH and there is a clear need for new therapies.
For further information, please contact:
| || |
T: +44 1625 469 920
| || |
| || |
T: +44 20 7894 7000
| || |
| || |
T: +44 20 3705 9330
T: +44 20 3727 1000
| || |
Redx is a
If you would like to sign up to regular alerts from
About NASH (Non-alcoholic Steatohepatitis)
NASH is an inflammatory and fibrotic disease of the liver that develops following non-alcoholic fatty liver disease (NAFLD) - a condition where fatty deposits build-up in liver tissue. It is estimated around 25-30% of adults in the developed world have NAFLD, with fatty liver often caused by diabetes, obesity, poor diet and lack of exercise. Whilst lifestyle changes can reverse NAFLD in the early stages, this goal is unachievable for most patients, and the progressive inflammation leads to tissue remodelling and fibrosis to the extent where the disease is no longer reversible with changes in patient lifestyle. Fibrotic tissue build-up results in loss of metabolic function in the liver and reduced blood flow, known as NASH. NASH progresses through different stages, each with increasing severity. In 2016, the prevalence of NASH F1-F3 worldwide was approximately 44 million with numbers expected to rise to 67 million by 20301. In the final stages (F4), patients have a condition known as cirrhosis, a severely debilitating disease caused by a heavily scarred liver with minimal function remaining. The worldwide prevalence of F4 cirrhosis was 3.6 million in 2016 and is set to more than double to 8.2 million by 20301. These cirrhosis patients are also at high risk of developing hepatocellular carcinoma (HCC), the third leading cause of cancer deaths worldwide. There are currently no approved treatments for NAFLD or NASH and there is a need for new therapies to address these diseases and specifically the treatment of fibrosis that causes loss of liver function.
About ROCK2 (Rho-associated protein kinase 2) inhibitors
ROCK2 is an intracellular kinase with multiple cellular functions. ROCK2 signalling plays a key role in both the inflammatory component and the tissue re-modelling that drives disease progression in many fibrotic conditions. ROCK2 has been shown to be up-regulated in acute inflammatory injury and in chronic diseases such as diabetes and metabolic syndrome. Furthermore, ROCK2 is upregulated in models of liver fibrosis and been shown to modulate activation of the hepatic stellate cells, the central drivers of fibrosis in the liver. Targeting ROCK2 in fibrosis is a clinically validated approach with Kadmon's KD025, a ROCK2 inhibitor in clinical development for IPF and cGVHD. However, this compound is potentially limited by its interaction with Cytochrome P450 enzymes which have led Kadmon to undertake clinical drug-drug interaction studies. The Redx ROCK2 selective inhibitor compound has a good ADME profile with a low propensity to inhibit key drug metabolising cytochrome P450 enzymes which is encouraging for clinical use in co-administration with concomitant medications in conditions such as NASH.
1. Estes et al,
This information is provided by RNS, the news service of the
Quick facts: Redx Pharma PLC
Market Cap: £117.64 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE